FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s

​Eisai and Biogen have announced that the US FDA has accepted for review the sBLA submitted by the former for Leqembi Iqlik SC-AI as a starting dose for early AD.

The post FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Philips unveils new InkSpace Snuggle coil for paediatric imaging
Lyell doses first patient in Phase III trial for LBCL
Natus Sensory acquires medical technology company TheraB Medical
MSD receives FDA approval for Keytruda combo to treat ovarian cancer
Patient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us